Brendan J. Guercio, M.D.
His areas of expertise include the use of cutting-edge immunotherapy, chemotherapy, and hormone therapy in the treatment of genitourinary cancers, with a focus on the development of new forms of therapy through clinical trials. Dr. Guercio has authored research articles in multiple journals including the Journal of Clinical Oncology. He has received Young Investigator Awards from the Bladder Cancer Advocacy Network (BCAN) and ASCO Conquer Cancer Foundation and has been a recipient of research support from the NIH/NCI.
Dr. Guercio previously served as an Instructor of Medicine at Harvard Medical School and as a Visiting Investigator at Memorial Sloan Kettering Cancer Center.
Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)
Residency & Fellowship
Fellowship, Hematology & Oncology, Memorial Sloan-Kettering Cancer Center. 2019 - 2022
Residency, Internal Medicine, Brigham & Womens Hospital. 2015 - 2018
MD | Harvard Medical School. 2015
Lead Researcher: Brendan J Guercio
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy....